BioSpace News Archive

Suction coagulators are used for controlled fluid evacuation. They also provide coagulation and suction procedures simultaneously.

Stem cells refer to special cells created by bone marrow of an individual. The key specialty of these cells is their ability to turn into various types of blood cells.

Neurological diseases have affected millions around the globe, and are known to be one of the worst kinds of maladies that can strike absolutely anyone.

Krabbe Disease is an inherited condition that tends to destroy the coatings of the nerve cells (Myelin) in the central nervous system and brain.

The market for fill-finish manufacturing is gaining significant impetus across the world. The constant technological advancements in fill-finish products and the increasing uptake of prefilled syringes are boosting the growth in this market.

Swabs are used for forensic purposes. These are specially developed for proper sample detection, analyzes, and securing the remains and traces left at the crime scene.

Immune thrombocytopenia is an autoimmune-mediated hematological disorder affecting the platelets. The immune system of the patient with immune thrombocytopenia produces antibodies directed against platelet antigens, causing platelet destruction and suppression of platelet production in the bone marrow cells.

Amryt, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that the U.S. Food and Drug Administration has granted Priority Review for Amryt’s New Drug Application for Oleogel-S10 for the treatment of Epidermolysis Bullosa.

Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the National Medical Products Administration of China has approved the supplemental New Drug Application for TYVYT® in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer.

Achieve Life Sciences, Inc. announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 16/993,522 and U.S. Patent Application No. 17/101,686 covering the novel 3.0 mg three times daily cytisinicline dosing regimen.